Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides
- 1 April 1998
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 36 (4) , 1020-7
- https://doi.org/10.1128/jcm.36.4.1020-1027.1998
Abstract
During the last several years a series of staphylococcal isolates that demonstrated reduced susceptibility to vancomycin or other glycopeptides have been reported. We selected 12 isolates of staphylococci for which the vancomycin MICs were ≥4 μg/ml or for which the teicoplanin MICs were ≥8 μg/ml and 24 control strains for which the vancomycin MICs were ≤2 μg/ml or for which the teicoplanin MICs were ≤4 μg/ml to determine the ability of commercial susceptibility testing procedures and vancomycin agar screening methods to detect isolates with reduced glycopeptide susceptibility. By PCR analysis, none of the isolates with decreased glycopeptide susceptibility contained known vancomycin resistance genes. Broth microdilution tests held a full 24 h were best at detecting strains with reduced glycopeptide susceptibility. Disk diffusion did not differentiate the strains inhibited by 8 μg of vancomycin per ml from more susceptible isolates. Most of the isolates with reduced glycopeptide susceptibility were recognized by MicroScan conventional panels and Etest vancomycin strips. Sensititre panels read visually were more variable, although with some of the panels MICs of 8 μg/ml were noted for these isolates. Vitek results were 4 μg/ml for all strains for which the vancomycin MICs were ≥4 μg/ml. Vancomycin MICs on Rapid MicroScan panels were not predictive, giving MICs of either ≤2 or ≥16 μg/ml for these isolates. Commercial brain heart infusion vancomycin agar screening plates containing 6 μg of vancomycin per ml consistently differentiated those strains inhibited by 8 μg/ml from more susceptible strains. Vancomycin-containing media prepared in-house showed occasional growth of susceptible strains, Staphylococcus aureus ATCC 29213, and on occasion, Enterococcus faecalis ATCC 29212. Thus, strains of staphylococci with reduced susceptibility to glycopeptides, such as vancomycin, are best detected in the laboratory by nonautomated quantitative tests incubated for a full 24 h. Furthermore, it appears that commercial vancomycin agar screening plates can be used to detect these isolates.Keywords
This publication has 41 references indexed in Scilit:
- Emerging multiply resistant enterococci among clinical isolates I. Prevalence data from 97 medical center surveillance study in the United StatesDiagnostic Microbiology and Infectious Disease, 1995
- Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unitAntimicrobial Agents and Chemotherapy, 1994
- Characterization of glycopeptide-resistant enterococci from U.S. hospitalsAntimicrobial Agents and Chemotherapy, 1993
- RP 59500, a new streptogramin highly active against recent isolates of North American staphylococciDiagnostic Microbiology and Infectious Disease, 1993
- Characterization of Staphylococcus aureus Isolates with Decreased Susceptibility to Vancomycin and Teicoplanin: Isolation and Purification of a Constitutively Produced Protein Associated with Decreased SusceptibilityThe Journal of Infectious Diseases, 1992
- Co-transfer of vancomycin and other resistance genes fromEnterococcus faecalisNCTC 12201 toStaphylococcus aureusFEMS Microbiology Letters, 1992
- Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureusFEMS Microbiology Letters, 1992
- Plasmid-Mediated Resistance to Vancomycin and Teicoplanin in Enterococcus FaeciumNew England Journal of Medicine, 1988
- VANCOMYCIN-RESISTANT ENTEROCOCCIThe Lancet, 1988
- THE STRUCTURE AND MODE OF ACTION OF GLYCOPEPTIDE ANTIBIOTICS OF THE VANCOMYCIN GROUPAnnual Review of Microbiology, 1984